• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Thromb Res . Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors

tetano

Editor, Senior Moderator
Thromb Res


. 2022 Aug 28;218:171-176.
doi: 10.1016/j.thromres.2022.08.021. Online ahead of print.
Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors


Minna Voigtlaender[SUP] 1 [/SUP], Carolin Edler[SUP] 2 [/SUP], Moritz Gerling[SUP] 2 [/SUP], Julia Schädler[SUP] 2 [/SUP], Benjamin Ondruschka[SUP] 2 [/SUP], Ann Sophie Schröder[SUP] 2 [/SUP], Jan Sperhake[SUP] 2 [/SUP], Stephan Ehrhardt[SUP] 3 [/SUP], Lin Wang[SUP] 3 [/SUP], Munif Haddad[SUP] 4 [/SUP], Verena Kiencke[SUP] 4 [/SUP], Thomas Renné[SUP] 5 [/SUP], Kevin Roedl[SUP] 6 [/SUP], Stefan Kluge[SUP] 6 [/SUP], Dominic Wichmann[SUP] 6 [/SUP], Florian Langer[SUP] 7 [/SUP]



Affiliations

Abstract

Background: Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in respiratory syndromes but also in vascular complications such as thromboembolism (TE). In this regard, immunothrombosis, resulting from inflammation in SARS-CoV-2 infected tissues, has been described. Data on TE in COVID-19 are mainly based on clinical observational and/or incomplete autopsy studies. The true burden of TE and the relevance of genetic predisposition, however, have not been resolved.
Objectives: Here, we report on a consecutive cohort of 100 fully autopsied patients deceased by SARS-CoV-2 infections during the first wave of the pandemic (March to April 2020). We investigated the localization of TE, potential clinical risk factors, and the prothrombotic gene mutations, factor V Leiden and prothrombin G20210A, in postmortem blood or tissue samples.
Results: TE was found in 43/100 autopsies. 93 % of TE events were venous occlusions, with 23 patients having pulmonary thromboembolism (PT) with or without lower-extremity deep vein thrombosis. Of these, 70 % showed PT restricted to (sub)segmental arteries, consistent with in situ immunothrombosis. Patients with TE had a significantly higher BMI and died more frequently at an intensive care unit. Hereditary thrombophilia factors were not associated with TE.
Conclusions: Our autopsy results show that a significant proportion of SARS-CoV-2 infected patients suffer from TE, affecting predominantly the venous system. Orthotopic peripheral PT was the most frequent finding. Hereditary thrombophilia appears not to be a determinant for TE in COVID-19. However, obesity and the need for intensive care increase the risk of TE in these patients.

Keywords: Autopsy; Body mass index; COVID-19; Hereditary thrombophilia; Intensive care unit; Thromboembolism.
 
Back
Top Bottom